You Position: Home > Paper
Experimental study on target intervention of mesenchymal stem cells in patients with multiple myeloma with As2O3
( views:325, downloads:104 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1009-9921.2007.04.003
- Key Word:
- 三氧化二砷;凋亡;细胞因子;间充质干细胞;多发性骨髓瘤
Abstract： 目的 分析三氧化二砷(As2O3)对多发性骨髓瘤(MM)患者骨髓间充质干细胞(MSC)凋亡及其IL-6、IL-1β、SCF表达的影响,探讨As2O3可能的新的作用机制和MSC作为治疗靶点的可行性.方法 含10%FBS的1640培养液培养MSC,以终浓度为0、0.2、0.4、0.6、0.8 μmol/L的As2O3作用MSC 8 h,倒置光学显微镜和Annexin V/FITC-PI双染法荧光显微镜下观察细胞凋亡,RT-PCR检测分析IL-6、IL-1β、SCF细胞因子表达的变化.结果 As2O3以浓度依赖方式诱导MM患者MSC凋亡,细胞胞膜皱缩,胞核解体,凋亡小体形成;As2O3抑制MSC IL-6、IL-1β、SCF的表达,药物浓度在0～0.6 μmol/L时对IL-1β的抑制与浓度成正比关系,浓度大于0.6 μmol/L时对IL-1β的抑制作用无显著差别,对IL-6和SCF的抑制呈药物浓度依赖性.结论 As2O3能诱导MM患者MSC的凋亡,明显抑制其IL-6、IL-1β、SCF的表达,这可能是有效治疗MM的靶点和机制之一.
- [1]沈文怡,陆化,唐宇宏,等.多发性骨髓瘤骨髓间充质干细胞多种细胞因子的异常表达[J].2005,(4).
- [2]Anderson KC,Chauhan D,Hideshima T,etc.Cytokines and signal transduction.[J].2005,18(4).
- [3]Wenrong, Xu,Hui, Qian,Wei, Zhu,etc.A novel tumor cell line cloned from mutated human embryonic bone marrow mesenchymal stem cells.[J].2004,12(3).
- [4]Toshiaki, Hayashi,Teru, Hideshima,Masaharu, Akiyama,etc.Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.[J].2002,1(10).
- [5]P, Rousselot,S, Labaume,J P, Marolleau,etc.Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients.[J].1999,59(5).
- [6]J A, Lust,K A, Donovan.The role of interleukin-1 beta in the pathogenesis of multiple myeloma.[J].1999,13.
- [7]Lust JA,Gertz MA,Donovan KA,etc.IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma.[J].2002,16(3).
- [8]Valérie Costes,Marielle Portier,Zhao-Yang Lu,etc.Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production[J].1998,103(4).
- [9]S R, Wallace,M M, Oken,K L, Lunetta,etc.Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.[J].2001,91(7).